ES2173049A2 - Monoestrer de acido graso y estrogeno como agente antidiabetico e hipolipemiante. - Google Patents

Monoestrer de acido graso y estrogeno como agente antidiabetico e hipolipemiante.

Info

Publication number
ES2173049A2
ES2173049A2 ES200100785A ES200100785A ES2173049A2 ES 2173049 A2 ES2173049 A2 ES 2173049A2 ES 200100785 A ES200100785 A ES 200100785A ES 200100785 A ES200100785 A ES 200100785A ES 2173049 A2 ES2173049 A2 ES 2173049A2
Authority
ES
Spain
Prior art keywords
estrone
oleoyl
acid monoester
hypolipidaemic
oestrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200100785A
Other languages
English (en)
Other versions
ES2173049R (es
ES2173049B1 (es
Inventor
Lamana Mariano Alemany
Betlloch Francisco Jav Remesar
Lopez Jose Antonio Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OLEOYL ESTRONE DEVELOPMENTS S
Original Assignee
OLEOYL ESTRONE DEVELOPMENTS S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200100785A priority Critical patent/ES2173049B1/es
Application filed by OLEOYL ESTRONE DEVELOPMENTS S filed Critical OLEOYL ESTRONE DEVELOPMENTS S
Priority to PCT/ES2002/000151 priority patent/WO2002076465A1/es
Priority to JP2002574979A priority patent/JP2004525141A/ja
Priority to CA002441890A priority patent/CA2441890A1/en
Priority to EP02720008A priority patent/EP1380300A1/en
Priority to US10/473,068 priority patent/US20040138193A1/en
Priority to AU2002251080A priority patent/AU2002251080B2/en
Publication of ES2173049A2 publication Critical patent/ES2173049A2/es
Publication of ES2173049R publication Critical patent/ES2173049R/es
Application granted granted Critical
Publication of ES2173049B1 publication Critical patent/ES2173049B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Monoéster de ácido graso y estrógeno como agente antidiabético e hipolipemiante. La oleoil-estrona o monooleato de estrona es un monoéster de un ácido graso y de un estrógeno que resulta ser apropiado para la preparación de un medicamento para el tratamiento y/o la profilaxis de un ser humano que padece una enfermedad metabólica seleccionada del grupo que forman la diabetes mellitus de tipo 2, la hiperlipemia (hipertriacilgliceridemia, hipercolesterolemia, hiperlipoproteinemia) y el Síndrome Metabólico X asociado a intolerancia a la glucosa, hiperinsulinemia o resistencia a la insulina. Comparado con la insulina, la oleoil-estrona tiene la ventaja de ser administrada por vía oral. La efectividad de la oleoil-estrona como antidiabético oral es conspicua puesto que no actúa sólo como un agente hipoglucemiante, sino que va a la raíz del problema, disminuyendo la resistencia a la insulina. Los efectos hipolipemiantes adicionales permiten extender su uso para el tratamiento de las dislipemias.
ES200100785A 2001-03-28 2001-03-28 Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante. Expired - Fee Related ES2173049B1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES200100785A ES2173049B1 (es) 2001-03-28 2001-03-28 Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante.
JP2002574979A JP2004525141A (ja) 2001-03-28 2002-03-25 抗糖尿病ならびに低脂血症薬としてのエストロゲン脂肪酸モノエステル
CA002441890A CA2441890A1 (en) 2001-03-28 2002-03-25 Oestrogen and fatty acid monoester as a hypolipidaemic and antidiabetic agent
EP02720008A EP1380300A1 (en) 2001-03-28 2002-03-25 Oestrogen and fatty acid monoester as a hypolipidaemic and antidiabetic agent
PCT/ES2002/000151 WO2002076465A1 (es) 2001-03-28 2002-03-25 Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante
US10/473,068 US20040138193A1 (en) 2001-03-28 2002-03-25 Oestrogen fatty acid monoester as a hypolipidaemic and antidiabetic agent
AU2002251080A AU2002251080B2 (en) 2001-03-28 2002-03-25 Oestrogen and fatty acid monoester as a hypolipidaemic and antidiabetic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100785A ES2173049B1 (es) 2001-03-28 2001-03-28 Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante.

Publications (3)

Publication Number Publication Date
ES2173049A2 true ES2173049A2 (es) 2002-10-01
ES2173049R ES2173049R (es) 2002-10-16
ES2173049B1 ES2173049B1 (es) 2004-01-16

Family

ID=8497326

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100785A Expired - Fee Related ES2173049B1 (es) 2001-03-28 2001-03-28 Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante.

Country Status (7)

Country Link
US (1) US20040138193A1 (es)
EP (1) EP1380300A1 (es)
JP (1) JP2004525141A (es)
AU (1) AU2002251080B2 (es)
CA (1) CA2441890A1 (es)
ES (1) ES2173049B1 (es)
WO (1) WO2002076465A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003294489A1 (en) * 2002-11-20 2004-06-15 Michael P. Girouard Combination of monounsaturated fatty acids and estrogen, and their use
EP2369346B1 (en) * 2006-03-24 2014-08-27 Metanomics GmbH Method for diagnosing diabetes type II
WO2011007882A1 (ja) * 2009-07-16 2011-01-20 国立大学法人九州大学 インスリン産生細胞誘導剤、グルコース取込み促進剤および糖尿病または糖尿病合併症の治療薬

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771817A2 (en) * 1995-10-30 1997-05-07 Laboratorios S.A.L.V.A.T., S.A. Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157031A (en) * 1983-08-02 1992-10-20 Research Corporation Technologies, Inc. Method for prophylaxis of obesity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771817A2 (en) * 1995-10-30 1997-05-07 Laboratorios S.A.L.V.A.T., S.A. Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALEMANY, M. y col. Oral oleoyl-estrone effects on insulin resistance of Zucker obese rats. International Journal of Obesity. Mayo 2000, Vol. 24, No Supplement 1, pagina S76, ISSN 0307-0565. Todo el documento. *
VIRGILI, J. y col. Distribution of oleoyl estrone in rat plasma lipoproteins. 1999, Vol. 31, No 11, paginas 597-601, ISSN 0018-5043. Resumen. *

Also Published As

Publication number Publication date
EP1380300A1 (en) 2004-01-14
CA2441890A1 (en) 2002-10-03
US20040138193A1 (en) 2004-07-15
AU2002251080B2 (en) 2007-02-01
WO2002076465A1 (es) 2002-10-03
ES2173049R (es) 2002-10-16
ES2173049B1 (es) 2004-01-16
JP2004525141A (ja) 2004-08-19

Similar Documents

Publication Publication Date Title
CA2382480A1 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
RU2470016C2 (ru) Производное бипиразола
CO5440230A1 (es) Nuevo compuesto heterociclico que comprende tetrahidroisoquinolina y una sal farmaceuticamente aceptable del mismo
JP2002543065A5 (es)
WO2002024180A3 (en) Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia
CA2402609A1 (en) Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
CA2371723A1 (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
IL112515A (en) Pharmaceutical composition containing N,N-dimethyl-1-¬1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine for use in the treatment of non-insulin dependent diabetes mellitus
JP2010514831A5 (es)
CA2439838A1 (en) (2-hydroxy)ethyl-thioureas useful as modulators of alpha2b adrenergic receptors
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
EP1067109A4 (en) CARBOXYLIC ACID DERIVATIVES AND MEDICAMENTS CONTAINING THESE DERIVATIVES AS ACTIVE INGREDIENT
CA2408142A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MX2011008416A (es) Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
EP1088824A3 (en) Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
JP2004524312A5 (es)
EP2902025A1 (en) Therapeutic agent for dyslipidemia
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
WO2002042271A3 (en) Biphenylcarboxamides useful as lipid lowering agents
CA2577497A1 (en) 15.beta.-substituted steroids having selective estrogenic activity
WO2000041504A3 (en) Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides
WO2007010281A3 (en) Use of thiazole derivatives and analogues in disorders caused by free fatty acids
NO983770L (no) Terapeutisk middel for diabetes
JO2390B1 (en) Diphenylcarboxamides act as lipid-lowering agents
WO2001000566A3 (en) Substituted phenoxyacetic acids

Legal Events

Date Code Title Description
EC2A Search report published

Ref document number: 20021019

Effective date: 20021019

FD2A Announcement of lapse in spain

Effective date: 20180807